Wed, Oct 1, 2014, 2:28 AM EDT - U.S. Markets open in 7 hrs 2 mins


% | $
Quotes you view appear here for quick access.

Advanced Medical Isotope Corporation Message Board

  • itrader250 itrader250 Aug 12, 2014 9:17 PM Flag

    Quarterly Filing, FDA, RadioGel, Battelle, everything coming together for ADMD

    pps is a gift at these prices, and most have been loading because they believe in the future, which is RadioGel. Battelle acquired 11% because they know how BIG it will be, once FDA approval comes. It's coming, don't kind yourself. We will see the next Q filing, should clear up a few things.

    Long N Strong, ADMD's RadioGel is the Future of Brackytherpy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • stay tuned, Q coming

    • * Pursue FDA clearance for Y-90 Brackytherapy products
      * Subject to receipt of funding, pursue international regulatory approval for Y-90 brachytherapy products
      * Secure partners for manufacturing and distribution of Y-90 brackytherapy products in the US
      * Secure license agreement for foreign production, distribution and sales of Y-90 brackytherapy products
      * Initial focus on Y-90 Fast-Resorbable Polymer Seeds and Y-90 RadioGel Device, followed by Y-90 Polymer Topical Paste.

      • 1 Reply to itrader250
      • Short of announcing FDA approval for AMIC’s brachytherapy products, I believe the PR today is probably the most exciting news AMIC could reasonably expect to receive for its future prospects. Battelle Memorial Institute – the extremely highly regarded scientific and medical research institution with 22,000 employees, global operations and last year revenues exceeding $6.2 billion, has acquired about a 10% interest in AMIC.

        Battelle developed the underlying patents for AMIC’s brachytherapy products and has partnered with AMIC on several research assignments.

        By taking this interest in AMIC, Battelle:

        1. Marries a significant equity interest to its patent license, re-emphasizing Battelle’s collaboration with AMIC to support the brachytherapy products as a break-through in treating cancer;

        2. Sends an unmistakable message to the FDA, regulators worldwide and potential customers that AMIC is not alone, but, rather, has the support of what is probably the world’s leading non-profit scientific and medical research institute. I believe that is the most powerful endorsement AMIC could ever hope to obtain; and

        3. Improves AMIC’s balance sheet by converting payables and costs associated with Battelle’s support to an equity position.

        Google Battelle. If you don’t know what Battelle is, this news may seem good but not awesome. But if, like the regulators AMIC must work with and the potential licensees and business partners AMIC will work with worldwide, you learn about what Battelle is to the science and medical communities, then you will understand why I see this news as so significant.

0.0036-0.0001(-2.70%)Sep 30 3:53 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Civeo Corporation
NYSETue, Sep 30, 2014 4:04 PM EDT
Sarepta Therapeutics, Inc.
NasdaqGSTue, Sep 30, 2014 4:15 PM EDT